FindTrial
Sign In

tetanus toxoid helper peptide

BIOLOGICAL6 trials

Sponsors

University of Virginia, Craig L Slingluff, Jr, Robert Ferris

Conditions

Fallopian Tube CancerHead and Neck CancerIntraocular MelanomaMalignant Conjunctival NeoplasmMelanoma (Skin)Ovarian CancerPrimary Peritoneal Cavity Cancer

Phase 1

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer
CompletedNCT00091273
University of VirginiaOvarian Cancer, Primary Peritoneal Cavity Cancer
Start: 2004-06-30End: 2007-06-30Updated: 2014-06-20
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
CompletedNCT00118313
Craig L Slingluff, JrMelanoma (Skin)
Start: 2004-11-04End: 2006-07-28Updated: 2020-03-27
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
CompletedNCT00118274
Craig L Slingluff, JrMelanoma (Skin)
Start: 2005-03-31End: 2010-02-28Updated: 2021-04-20
Vaccine Therapy in Treating Patients With Head and Neck Cancer
CompletedNCT00404339
Robert FerrisHead and Neck Cancer
Start: 2005-09-30End: 2014-03-31Updated: 2016-04-18
Vaccine Therapy in Treating Patients With Advanced Melanoma
CompletedNCT00705640
Craig L Slingluff, JrIntraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
Start: 2008-05-31Updated: 2016-12-16

Phase 2

Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
TerminatedNCT00373217
Craig L Slingluff, JrFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Start: 2006-04-13End: 2008-02-07Updated: 2022-09-21

Related Papers

Adverse Events as a Function of Biological Sex in a Multicenter Clinical Trial of Melanoma Vaccines
Cancers2024-11-201 citations
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.
2024-03-2220 citations
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
Journal for ImmunoTherapy of Cancer2021-08-0158 citations
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
Journal for ImmunoTherapy of Cancer2020-04-0132 citations
Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis.
2010-08-2033 citations